2871 related articles for article (PubMed ID: 12512736)
21. Antithrombotic drugs for the secondary prevention of ischemic stroke.
Nenci GG; Goracci S
Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
[TBL] [Abstract][Full Text] [Related]
22. [The best of epidemiology and cardiovascular prevention in 2006].
Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
[TBL] [Abstract][Full Text] [Related]
23. Combination antithrombotic therapy with antiplatelet agents and anticoagulants for patients with atherosclerotic heart disease.
Arjomand H; Cohen M; Ezekowitz MD
J Invasive Cardiol; 2004 May; 16(5):271-8. PubMed ID: 15152137
[TBL] [Abstract][Full Text] [Related]
24. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease.
Mehta SR; Yusuf S;
Eur Heart J; 2000 Dec; 21(24):2033-41. PubMed ID: 11102254
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet drugs in cardiovascular prevention: coronary events: acute phase and secondary prevention.
Prescrire Int; 2000 Jun; 9(47):83-5. PubMed ID: 11010749
[TBL] [Abstract][Full Text] [Related]
26. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
27. [Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
Magnani B; Semprini F
Cardiologia; 1994 Dec; 39(12 Suppl 1):15-21. PubMed ID: 7634259
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
29. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices.
Faxon DP
Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074
[TBL] [Abstract][Full Text] [Related]
30. Aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Annu Rev Public Health; 1997; 18():37-49. PubMed ID: 9143711
[TBL] [Abstract][Full Text] [Related]
31. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Motovska Z; Kala P
Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914
[TBL] [Abstract][Full Text] [Related]
32. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
33. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
34. Acute ischemic coronary artery disease and ischemic stroke: similarities and differences.
Fisher M; Folland E
Am J Ther; 2008; 15(2):137-49. PubMed ID: 18356634
[TBL] [Abstract][Full Text] [Related]
35. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial.
Bhatt DL; Flather MD; Hacke W; Berger PB; Black HR; Boden WE; Cacoub P; Cohen EA; Creager MA; Easton JD; Hamm CW; Hankey GJ; Johnston SC; Mak KH; Mas JL; Montalescot G; Pearson TA; Steg PG; Steinhubl SR; Weber MA; Fabry-Ribaudo L; Hu T; Topol EJ; Fox KA;
J Am Coll Cardiol; 2007 May; 49(19):1982-8. PubMed ID: 17498584
[TBL] [Abstract][Full Text] [Related]
36. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
; Alexander JH; Becker RC; Bhatt DL; Cools F; Crea F; Dellborg M; Fox KA; Goodman SG; Harrington RA; Huber K; Husted S; Lewis BS; Lopez-Sendon J; Mohan P; Montalescot G; Ruda M; Ruzyllo W; Verheugt F; Wallentin L
Circulation; 2009 Jun; 119(22):2877-85. PubMed ID: 19470889
[TBL] [Abstract][Full Text] [Related]
37. Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
Hankey GJ
Cerebrovasc Dis; 2004; 17 Suppl 3():11-6. PubMed ID: 14730253
[TBL] [Abstract][Full Text] [Related]
38. Antiplatelet drugs for ischemic stroke prevention.
Leys D; Balucani C; Cordonnier C
Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
[TBL] [Abstract][Full Text] [Related]
39. Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Gebel JM
Am J Cardiovasc Drugs; 2010; 10(2):115-24. PubMed ID: 20334449
[TBL] [Abstract][Full Text] [Related]
40. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration
BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
